NCT07243561 Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism
| NCT ID | NCT07243561 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Dongfang People's Hospital |
| Condition | Autism Spectrum Disorder (ASD |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-09-01 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical study aims to evaluate whether a nasal spray containing exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSC-EXOs) can safely and effectively improve core symptoms in children aged 3-7 years with autism spectrum disorder (ASD). It is a 24-week, non-randomized, controlled, open-label trial. Sixty pediatric patients with ASD will be non-randomly assigned at a 1:2 ratio to two groups: a no-intervention control group and an active exosome nasal spray treatment group. The treatment group will receive the nasal spray on Mondays, Wednesdays, and Fridays, totaling 10 administrations throughout the study. The no-intervention control group will receive no experimental treatment but will undergo the same assessments and safety checks with the treatment group. This design aims to monitor the safety and efficacy of the hUC-MSC-EXOs nasal spray.
Eligibility Criteria
Inclusion Criteria: * Diagnosis meets the ICD-11 ASD criteria or DSM-5 ASD clinical diagnostic standards. * No significant improvement in core symptoms was observed after ≥3 months of standardized behavioral intervention. * Score ≥30 on the CARS2, indicating mild-to-moderate or more severe autism. * Aged 3 (inclusive) to 7 (inclusive) years, regardless of gender * Voluntary participation in this clinical study, with written informed consent provided by the patient's legal guardian, and willingness to undergo examinations, treatment, and cooperate with follow-up visits. * In the investigator's judgment, the patient is capable of understanding and complying with study requirements. Exclusion Criteria: * History of severe allergic reactions. * Any severe mental disorder or other types of autism spectrum disorders. * History of epileptic seizures within the past six months. * Autism secondary to epilepsy, cerebrovascular disease, or traumatic brain injury. * Disease severity rated as normal, borderline mental disorder, or mild mental disorder on the Clinical Global Impression scale. * Moderate or severe extrapyramidal symptoms or tardive dyskinesia. * Severe self-injurious behavior. * Active systemic or severe localized infections, including human immunodeficiency virus, syphilis, and hepatitis. * Autoimmune diseases. * Major organ impairment. * Severe pulmonary or hematological diseases, malignancies, or immunodeficiency. * Concurrent treatments that may interfere with the safety and efficacy evaluation of stem cell therapy. * Participation in other clinical trials within the past three months. * Other clinical conditions deemed by investigators as unsuitable for study inclusion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07243561 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 7 Years, studying Autism Spectrum Disorder (ASD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07243561 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07243561 currently recruiting?
Yes, NCT07243561 is actively recruiting participants. Contact the research team at dfsrmyykjk@126.com for enrollment information.
Where is the NCT07243561 trial being conducted?
This trial is being conducted at Dongfang, China.
Who is sponsoring the NCT07243561 clinical trial?
NCT07243561 is sponsored by Dongfang People's Hospital. The trial plans to enroll 60 participants.